for Journals by Title or ISSN
for Articles by Keywords
help

Publisher: Informa plc   (Total: 10 journals)   [Sort by number of followers]

Showing 1 - 10 of 10 Journals sorted alphabetically
Agra Europe     Full-text available via subscription   (Followers: 3)
Arbitration Law Monthly     Full-text available via subscription   (Followers: 3)
Consumer Drugs     Full-text available via subscription  
IN VIVO     Full-text available via subscription   (Followers: 4, SJR: 0.409, CiteScore: 1)
Medtech Insight     Full-text available via subscription   (Followers: 2)
Money Laundering Bulletin     Full-text available via subscription   (Followers: 4)
START-UP     Full-text available via subscription   (Followers: 3)
The Pink Sheet     Full-text available via subscription   (Followers: 7)
The Pink Sheet Daily     Full-text available via subscription   (Followers: 3)
The Rose Sheet     Full-text available via subscription   (Followers: 2)
Journal Cover
START-UP
Number of Followers: 3  
 
  Full-text available via subscription Subscription journal
ISSN (Print) 1943-7358 - ISSN (Online) 1090-4417
Published by Informa plc Homepage  [10 journals]
  • Tech Transfer Deals, July 2016
    • Abstract: Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced May through June.
      PubDate: Tue, 05 Jul 2016 08:00:06 -040
       
  • Venture Funding Deals, July 2016
    • Abstract: Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced May through June.
      PubDate: Tue, 05 Jul 2016 08:00:01 -040
       
  • Blue Earth Wins FDA Approval For Prostate Cancer PET Tracer
    • Abstract: GE spin-out Blue Earth Diagnostics is betting that positron emission tomography imaging to aid recurrent prostate cancer treatment is an untapped market with the FDA approval of its Axumin molecular imaging agent.
      PubDate: Tue, 28 Jun 2016 00:00:10 -040
       
  • Vedanta Raises $50 Million For Microbiome Candidate Trials
    • Abstract: Vedanta Biosciences, which is developing a new class of therapies designed to modulate the human microbiome, has raised $50 million through new equity investments to advance several of its programs into the clinic.
      PubDate: Tue, 28 Jun 2016 00:00:01 -040
       
  • Immuno-Oncology Attracts Big Deal Dollars For Biotechs
    • Abstract: Biotechs in the immuno-oncology space can’t operate in a vacuum. To attract funding and partners, their drug candidates must show potential to not only surpass available treatments, but also have the ability to work in tandem with them.
      PubDate: Mon, 27 Jun 2016 11:35:00 -040
       
  • BioDirection Inc.
    • Abstract: BioDirection Inc. is poised to launch what it says is the first objective point-of-care test for diagnosing concussion and other traumatic brain injuries. Based on proprietary nanotechnology, the company’s Tbit device detects molecular levels of two crucial brain biomarkers that are released into the bloodstream immediately after a brain injury, from just a single drop of blood in less than two minutes.
      PubDate: Thu, 23 Jun 2016 13:00:00 -040
       
  • Ariste Medical LLC
    • Abstract: Ventral hernia repair is associated with a relatively high incidence of microbial contamination of the surgical site, ranging from 8% to 40%. To combat infection, Ariste Medical LLC has developed a mid-weight hernia mesh that features a proprietary polymer coating embedded with a programmed release of two proven antimicrobials.
      PubDate: Wed, 22 Jun 2016 09:00:00 -040
       
  • From The Editor: A New Chapter For Start-Up
    • Abstract: For 20 years, you've depended on Start-Up for in-depth, insightful analysis of emerging life sciences companies, trends and technologies. We are delighted to announce some upcoming enhancements to your service.
      PubDate: Tue, 21 Jun 2016 07:30:01 -040
       
  • Homology Medicines Inc.
    • Abstract: Gene editing has made a great many headlines of late, and one could be forgiven for thinking the field was saturated, but Homology Medicines Inc. offers something new. Its platform relies on a different mechanism, known as homologous recombination, and the start-up's management team believes the approach can get around some of the potential limitations found in other gene-editing technologies.
      PubDate: Fri, 17 Jun 2016 08:00:00 -040
       
  • HealthQuest Seeks Start-Ups That Hit Health Care’s Bottom Line
    • Abstract: Founded with the intent to invest in companies that bring value to health care, HealthQuest Capital continues to find strong interest from limited partners and unique companies to back.
      PubDate: Wed, 15 Jun 2016 14:15:04 -040
       
  • Infectious Disease Companies Catch More Investors
    • Abstract: Start-Up surveyed investments into, and exits by, private infectious disease-focused companies from 2013 through the first quarter of 2016, using data from Informa’s Pharma Intelligence's Strategic Transactions and Medtrack databases. Our review reveals an increasing amount of money going into these firms, especially those developing novel antibiotics against drug-resistant bacteria or with novel anti-infective drug development platforms.
      PubDate: Tue, 14 Jun 2016 07:30:01 -040
       
  • Start-Up Execs On The Move, June 2016
    • Abstract: Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.
      PubDate: Fri, 10 Jun 2016 09:10:02 -040
       
  • Cardialen Inc.
    • Abstract: Cardialen's hybrid implantable pacemaker/defibrillator for atrial fibrillation monitors the heart beat by beat. At the first sign of arrhythmia it delivers a low-level electrical pulse to convert the patient's irregularity back to a normal heart rhythm.
      PubDate: Tue, 07 Jun 2016 08:00:00 -040
       
  • Tech Transfer Deals, June 2016
    • Abstract: Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced April through May 2016.
      PubDate: Thu, 02 Jun 2016 08:00:07 -040
       
  • Venture Funding Deals, June 2016
    • Abstract: Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced April through May 2016.
      PubDate: Thu, 02 Jun 2016 08:00:01 -040
       
  • Advanced Cooling Therapy Inc.
    • Abstract: Advanced Cooling Therapy Inc. has developed a novel device that control's a patient’s entire body temperature by either heating or cooling blood surrounding the esophagus.
      PubDate: Thu, 26 May 2016 00:00:26 -040
       
  • Aptinyx Cashes In Post-Naurex Cache With $65 Million Series A
    • Abstract: Aptinyx, a biotechnology firm developing small molecules that modulate the NMDA receptor to treat neurological disorders, closed a $65 million Series A round, capitalizing on the cache that its management team gained from the sale of Naurex to Allergan.
      PubDate: Thu, 26 May 2016 00:00:21 -040
       
  • PureTech Enters CAR-T With Vor BioPharma
    • Abstract: PureTech Health says its new start-up Vor BioPharma is advancing a novel approach to chimeric antigen receptor (CAR) T-cell therapy that has the potential to broaden the science's applicability and success rate in other cancers – but it's not willing to say exactly how it will do that.
      PubDate: Thu, 26 May 2016 00:00:01 -040
       
  • PeptiMimesis
    • Abstract: PeptiMimesis is developing first-in-class transmembrane therapeutic peptides with potential in immuno-oncology, oncology and immune diseases. Its technology is based on research showing that targeting the transmembrane domain using a single peptide can block several of the processes involved in the development of cancer by disrupting dimerization of target receptors, impairing the formation of receptor complexes and indirectly blocking the subsequent signaling pathways
      PubDate: Wed, 25 May 2016 07:00:01 -040
       
  • MiNDERA Corp.
    • Abstract: MiNDERA Corp. is developing an alternative to punch biopsies for diagnosing skin cancer: its microneedle device extracts biomarkers from the skin in a procedure that the start-up says is highly accurate and cost-effective for office-based diagnostic applications in dermatology.
      PubDate: Tue, 24 May 2016 12:30:01 -040
       
  • Bioqube Takes The Reins At J&J Innovation's JLINX
    • Abstract: The recently launched venture capital firm has partnered with J&J Innovation to manage its new European life sciences incubator. START-UP speaks with bioqube's managing partner Nico Vandervelpen.
      PubDate: Fri, 20 May 2016 09:00:00 -040
       
  • 4Tech Inc.
    • Abstract: 4Tech Inc. has developed a dedicated transcatheter system to treat tricuspid regurgitation. ItsTriCinch applies tension to an anchor placed on the annulus of the tricuspid valve, thus reducing the size of the native annulus and limiting the amount of blood that can backflow through the valve.
      PubDate: Thu, 19 May 2016 09:15:01 -040
       
  • Regenerative Immunology: Immunotherapy’s Next Frontier?
    • Abstract: A recent publication shows that T helper 2 cells play a critical role in creating a pro-regenerative microenvironment when biomaterial scaffolds are inserted into the body to promote wound healing.
      PubDate: Wed, 18 May 2016 08:30:00 -040
       
  • FemPulse Pioneers On Multiple Fronts
    • Abstract: Medtech start-up FemPulse is pursuing a novel neuromodulation approach to treating overactive bladder. START-UP talks to founder and president Alexandra Haessler MD, herself something of a novelty in the mostly-male world of medtech entrepreneurship.
      PubDate: Mon, 16 May 2016 08:00:14 -040
       
  • Enumeral Biomedical Holdings Inc.
    • Abstract: Checkpoint inhibitors have caused a sensation in oncology in recent years, but biotech Enumeral Biomedical Holdings Inc. is setting its sights on the Achilles' heel of the new antibodies – the high failure rate – using a discovery platform that employs cells from human biopsies, rather than more commonly used rodent models.
      PubDate: Fri, 13 May 2016 08:00:00 -040
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-